Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
28.91 USD | -5.12% | -5.21% | -43.58% |
07:53am | Roche enters obesity drug market with $2.7 bln Carmot deal | RE |
Dec. 02 | Health Up as Pfizer Slides -- Health Care Roundup | DJ |
Pfizer, Inc. the world's leading pharmaceutical group. Net sales break down by family of products as follows:
- vaccines (52.4%);
- drugs for the treatment of cancer (15.2%);
- cardiovascular, metabolic and analgesic drugs (11.5%);
- injectable, anti-infectives drugs and active pharmaceutical ingredients (9%);
- drugs for inflammatory and immune diseases (5.5%);
- drugs for rare diseases (4.4%);
- other (2%).
At the end of 2021, the group had more than 39 production sites worldwide.
Net sales are distributed geographically as follows: the United States (36.6%), Europe (22.6%) and other (40.8%).
Sector
Pharmaceuticals
Calendar
Trading Rating :
Investor Rating :
ESG Refinitiv :
C+
Sell
Buy

Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
28.91USD
Average target price
40.46USD
Spread / Average Target
+39.95%
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-43.58% | 163 B $ | |
+59.64% | 525 B $ | |
-10.34% | 381 B $ | |
-6.75% | 262 B $ | |
-11.26% | 253 B $ | |
-15.80% | 221 B $ | |
+2.68% | 202 B $ | |
-9.04% | 200 B $ | |
+3.74% | 146 B $ | |
-4.15% | 117 B $ |
- Stock
- Equities
- Stock Pfizer, Inc. - Nyse
- News Pfizer, Inc.
- AstraZeneca's Alexion Unit Completes Purchase of Pfizer's Gene Therapy Portfolio